# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Michael Schmidt initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target...
- SEC Filing
- SEC Filing
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $27 t...
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 4...
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting so...
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has be...
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of ...